TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36153547

Group type: EXPERIMENTAL
Intervention: Interactive book sharing intervention
Number of subjects: 115

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 115
Study: 32434492

Group type: EXPERIMENTAL
Intervention: Loneliness at baseline (measured using the UCLA Loneliness Scale)
Number of subjects: 399
Study: 616399850

Group type: EXPERIMENTAL
Intervention: Hands-on learning with a bench model simulator
Number of subjects: 86

Group type: COMPARATOR
Intervention: Video-learning using an instructional video
Number of subjects: 86
Study: 34172470

Group type: COMPARATOR
Intervention: Stopping mepolizumab (switch to placebo)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Continuing mepolizumab 100 mg every 4 weeks
Number of subjects: 295
Study: 34247980

Group type: EXPERIMENTAL
Intervention: GDFT-hydroxyethyl starch (GH)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: GDFT-lactated Ringer's (GL)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional fluid therapy (Control)
Number of subjects: 75
Study: 34909045

Group type: EXPERIMENTAL
Intervention: L-carnitine (1.5 g daily for six days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 36094578

Group type: COMPARATOR
Intervention: Cold-water immersion at 10°C (CON)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cold-water immersion at 17°C with 75.7L ice added (ICE)
Number of subjects: 12
Study: 33765054

Group type: EXPERIMENTAL
Intervention: Adenosine (18 mg intravenous bolus)
Number of subjects: 46
Study: 32831540

Group type: EXPERIMENTAL
Intervention: Posterior TAP block
Number of subjects: 82

Group type: COMPARATOR
Intervention: Lateral TAP block
Number of subjects: 82
Study: 34166000

Group type: EXPERIMENTAL
Intervention: Access to a decision support system (n = 335)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Treatment as usual (n = 203)
Number of subjects: 538
Study: 35430238

Group type: EXPERIMENTAL
Intervention: 10 mg ulipristal acetate daily
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 5 mg ulipristal acetate daily
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cyclic regimen of 5 mg ulipristal acetate for 24 days followed by four placebo days
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All ulipristal acetate treatments
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: BMI > 32 kg/m2
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Endometrial biopsies during treatment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 10 mg ulipristal acetate
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 5 mg ulipristal acetate
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cyclic regimen of 5 mg ulipristal acetate
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Liver transaminase changes
Number of subjects: 180
Study: 33496796

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 3100

Group type: COMPARATOR
Intervention: DC-ICD
Number of subjects: 3100
Study: 32847927

Group type: EXPERIMENTAL
Intervention: Levetiracetam or Zonisamide (new AEDs)
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Standard AED (lamotrigine for focal epilepsy, sodium valproate for generalized epilepsy)
Number of subjects: 1510

Group type: EXPERIMENTAL
Intervention: Levetiracetam (new AED)
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Standard AED (lamotrigine or sodium valproate)
Number of subjects: 1510
Study: 34792161

Group type: EXPERIMENTAL
Intervention: Higher dialysate sodium concentration (142 mmol/L)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Lower dialysate sodium concentration (138 mmol/L)
Number of subjects: 139
Study: 32562632

Group type: EXPERIMENTAL
Intervention: Late-parenteral nutrition
Number of subjects: 684

Group type: COMPARATOR
Intervention: Early-parenteral nutrition
Number of subjects: 684
Study: 33280489

Group type: EXPERIMENTAL
Intervention: Physical abuse without a weapon
Number of subjects: 3011

Group type: EXPERIMENTAL
Intervention: Physical abuse with a weapon
Number of subjects: 3011

Group type: EXPERIMENTAL
Intervention: Attempted rape without penetration
Number of subjects: 3011

Group type: EXPERIMENTAL
Intervention: Attempted rape with penetration
Number of subjects: 3011

Group type: EXPERIMENTAL
Intervention: Verbal sexual harassment
Number of subjects: 3011
Study: 32303829

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (4.03 mmol NO3- and 0.29 mmol NO2-)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 10
Study: 32125792

Group type: EXPERIMENTAL
Intervention: Restricted CF group (n=44)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Non-CF group (n=45)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study: 35112386

Group type: EXPERIMENTAL
Intervention: Essential Health Care Programme (EHCP) - daily toothbrushing with fluoride toothpaste
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: EHCP + Fluoride - weekly application of high-concentrated fluoride gel
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: EHCP + OUT - twice-yearly access to on-demand urgent oral treatment
Number of subjects: 682

Group type: COMPARATOR
Intervention: Control group - standard school-based oral health education
Number of subjects: 682
Study: 33649613

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control
Number of subjects: 220

Group type: COMPARATOR
Intervention: Nicorandil
Number of subjects: 220
Study: 32073559

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid eye drops (Group A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Gastroftal eye drops and tablets (Group B)
Number of subjects: 21
Study: 36481516

Group type: EXPERIMENTAL
Intervention: 3P intervention (combination of imaginal retraining and decoupling)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 227

Group type: COMPARATOR
Intervention: Active control conditions (two types)
Number of subjects: 227
Study: 34224598

Group type: EXPERIMENTAL
Intervention: Transcutaneous perineal electrostimulation (intervention group, IG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intracavitary anal electrostimulation (control group, CG)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both IG and CG
Number of subjects: 70
Study: 32126454

Group type: EXPERIMENTAL
Intervention: Current tobacco use
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Current tobacco use (adjusted)
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Other factors (age, marital status, financial status, education, pain severity)
Number of subjects: 798
Study: 34366425

Group type: EXPERIMENTAL
Intervention: Open-lung strategy (OLS) with PEEP of 6-8 cmH2O and repeated LRMs every 30 minutes
Number of subjects: 280

Group type: COMPARATOR
Intervention: Zero PEEP without LRMs (non-OLS group)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Open-lung strategy (OLS)
Number of subjects: 280
Study: 36090002

Group type: EXPERIMENTAL
Intervention: Jintiange capsules (1.2 g each time, 3 times per day) and alfacalcidol (0.25 μg/d)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Calcium carbonate (element calcium 0.3 g, twice a day) and alfacalcidol (0.25 μg/d)
Number of subjects: 400
Study: 36066032

Group type: EXPERIMENTAL
Intervention: 3D foot scanner app for selecting therapeutic footwear
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (aesthetic preferences for TF size and model)
Number of subjects: 30
Study: 35010445

Group type: EXPERIMENTAL
Intervention: e-mail-delivered cognitive behavioral therapy for insomnia (CBT-I) (REFRESH)
Number of subjects: 48

Group type: COMPARATOR
Intervention: self-monitoring (SM) with sleep diaries
Number of subjects: 48
Study: 34894470

Group type: EXPERIMENTAL
Intervention: 5 mg terazosin (TZ)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 34077998

Group type: EXPERIMENTAL
Intervention: Immune-related lncRNA prognostic signature model
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Risk score
Number of subjects: 356
Study: 32989771

Group type: EXPERIMENTAL
Intervention: Virtual parent-training program with e-learning modules and scripted role-play via a VPN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 0
Study: 34883313

Group type: EXPERIMENTAL
Intervention: Positive biomarker test result
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Mild and moderate symptoms of dementia
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Disease-modifying treatment available
Number of subjects: 1817
Study: 33646265

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific T cells
Number of subjects: 85
Study: 33127581

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control groups (computer control, device sham control, earlobe stimulation control)
Number of subjects: 37
Study: 35191198

Group type: EXPERIMENTAL
Intervention: Mouth rinse with hydrogen peroxide (H2 O2) and hyaluronic acid (HA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 50
Study: 34155684

Group type: EXPERIMENTAL
Intervention: Mendelian randomization using 395 genetic variants for systolic blood pressure
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Mendelian randomization using 391 genetic variants for diastolic blood pressure
Number of subjects: 786
Study: 36456480

Group type: EXPERIMENTAL
Intervention: Ergometrine combined with oxytocin (intra-myometrial injection following oxytocin intravenously)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Oxytocin alone (intra-myometrial injection following oxytocin intravenously)
Number of subjects: 298
Study: 33640941

Group type: EXPERIMENTAL
Intervention: Recommended non‐supervised physical activity (30 min/day) before and 4 weeks after surgery
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no advice regarding physical activity)
Number of subjects: 400
Study: 36420866

Group type: EXPERIMENTAL
Intervention: Honey (1 g kg-1 day-1) and Nigella sativa seeds (80 mg kg-1 day-1)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 33638129

Group type: EXPERIMENTAL
Intervention: Counterclockwise rotation of the occlusal plane (CCWROP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (without CCWROP)
Number of subjects: 38
Study: 32481277

Group type: EXPERIMENTAL
Intervention: Shexiang Tongxin Dropping Pills (STDP) combined with routine medicine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nicorandil combined with routine medicine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: STDP combined with routine medicine
Number of subjects: 72
Study: 33830503

Group type: EXPERIMENTAL
Intervention: Deep brain anterior thalamus stimulation
Number of subjects: 110
Study: 32332827

Group type: EXPERIMENTAL
Intervention: 40-Hz binaural beats (BB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 16-Hz binaural beats (BB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No sound (control condition)
Number of subjects: 0
Study: 35045943

Group type: EXPERIMENTAL
Intervention: Ticagrelor (Radial access)
Number of subjects: 3984

Group type: COMPARATOR
Intervention: Prasugrel (Radial access)
Number of subjects: 3984

Group type: EXPERIMENTAL
Intervention: Ticagrelor (Femoral access)
Number of subjects: 3984

Group type: COMPARATOR
Intervention: Prasugrel (Femoral access)
Number of subjects: 3984
Study: 32049331

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000/ferric derisomaltose (IIM) - single dose of 1000 mg IV
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Iron sucrose (IS) - administered as 200 mg IV injections up to five times within a 2-week period
Number of subjects: 1538
Study: 32619561

Group type: EXPERIMENTAL
Intervention: Calorically restricted ketogenic diet and intermittent fasting (KD‐IF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calorically unrestricted diet
Number of subjects: 50
Study: 33962354

Group type: EXPERIMENTAL
Intervention: Hybrid cognitive remediation (CR) with half sessions conducted remotely as homework
Number of subjects: 0

Group type: COMPARATOR
Intervention: All in-clinic cognitive remediation (CR)
Number of subjects: 0
Study: 32853164

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Older adolescents
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: All domains of aggression
Number of subjects: 453
Study: 35879217

Group type: EXPERIMENTAL
Intervention: Intermediate-dose prophylactic anticoagulation
Number of subjects: 375

Group type: COMPARATOR
Intervention: Standard-dose prophylactic anticoagulation
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 375
Study: 33900253

Group type: EXPERIMENTAL
Intervention: Flexible Periodization (FP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonflexible Periodization (NP)
Number of subjects: 32
Study: 35527624

Group type: EXPERIMENTAL
Intervention: GSI scanning protocol 1 (GSI profile: head and neck CTA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: GSI scanning protocol 2 (GSI profile: chest 80 mm)
Number of subjects: 100
Study: 34923901

Group type: EXPERIMENTAL
Intervention: Oral fecal microbiota transplantation (FMT) capsules for 12 weeks (A3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral empty capsules for 12 weeks (B3)
Number of subjects: 0
Study: 35553901

Group type: EXPERIMENTAL
Intervention: RBC membrane n‐3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: N‐6 polyunsaturated fatty acids (PUFAs)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Mono‐unsaturated fatty acids
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Total saturated fatty acids
Number of subjects: 192
Study: 32045259

Group type: EXPERIMENTAL
Intervention: Acupuncture plus antihypertensive drugs
Number of subjects: 70

Group type: COMPARATOR
Intervention: Antihypertensive drugs only (Control)
Number of subjects: 70
Study: 35714267

Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency neurolysis (TCRF) of the posterior nasal nerve (PNN) area
Number of subjects: 77

Group type: COMPARATOR
Intervention: Crossover to active treatment from sham-control
Number of subjects: 77
Study: 33537902

Group type: EXPERIMENTAL
Intervention: Kerr Life (KL)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: IRM zinc oxide eugenol cement (IRM)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ketac Bond (KB)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dycal (DY)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Vitrebond (VB)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: mineral trioxide aggregate (MTA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Prime&Bond NT (PB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 42
Study: 33203003

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (100 mg/day) and exercise
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo and exercise
Number of subjects: 31
Study: 35815739

Group type: EXPERIMENTAL
Intervention: omega-3 PUFA supplementation (1020 mg daily for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (weight loss diet only)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (omega-3 and control)
Number of subjects: 40
Study: 32566763

Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 361

Group type: COMPARATOR
Intervention: waiting-list
Number of subjects: 361
Study: 36129139

Group type: EXPERIMENTAL
Intervention: Mind Map group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 45
Study: 33857891

Group type: EXPERIMENTAL
Intervention: Increase in the number of grain boundaries from 3 to 25
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increase in crack length
Number of subjects: 0
Study: 32059855

Group type: EXPERIMENTAL
Intervention: Intraoperative hemoadsorption
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (surgery without hemoadsorption)
Number of subjects: 58
Study: 35584336

Group type: EXPERIMENTAL
Intervention: Elacestrant 400 mg orally once daily
Number of subjects: 477

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) endocrine monotherapy
Number of subjects: 477
Study: 32768551

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) plus usual care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (EA and control)
Number of subjects: 30
Study: 32706667

Group type: EXPERIMENTAL
Intervention: ICBT combined with serious gaming for 6 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 69
Study: 36401521

Group type: EXPERIMENTAL
Intervention: Lanolin treatment
Number of subjects: 206

Group type: COMPARATOR
Intervention: Human milk treatment
Number of subjects: 206
Study: 35367282

Group type: EXPERIMENTAL
Intervention: Seladelpar 2 mg/day
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Seladelpar 5 mg/day
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Seladelpar 10 mg/day
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Seladelpar 5 mg/day and 10 mg/day
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 119
Study: 32183815

Group type: EXPERIMENTAL
Intervention: Park Prescription Intervention (PPI): Face-to-face Park Prescription + invitation to weekly exercise sessions in parks
Number of subjects: 160
Study: 34046921

Group type: EXPERIMENTAL
Intervention: STR-324 (0.004-11.475 mg h-1)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: STR-324 (1.25-11.25 mg h-1)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 33252584

Group type: EXPERIMENTAL
Intervention: 1,000 centistoke silicone oil tamponade
Number of subjects: 302

Group type: COMPARATOR
Intervention: 14% to 16% silicone oil to perfluoropropane gas tamponade
Number of subjects: 302
Study: 32921466

Group type: EXPERIMENTAL
Intervention: 22AA milk replacer (MR) with greater EAA concentrations (24% CP) fed at 0.57 kg/d for 0-14 d, increased to 0.85 kg/d through 35 d, then 0.41 kg/d until weaning after 42 d.
Number of subjects: 40

Group type: COMPARATOR
Intervention: 22CP milk replacer (MR) (standard 22:20 CP:fat) fed at 0.57 kg/d for 0-14 d, increased to 0.85 kg/d through 35 d, then 0.41 kg/d until weaning after 42 d.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 22AA milk replacer (MR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 22CP milk replacer (MR)
Number of subjects: 40
Study: 32279536

Group type: EXPERIMENTAL
Intervention: Residual bootstrap with studentized CI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residual bootstrap with basic CI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Analytic methods
Number of subjects: 0
Study: 36218094

Group type: EXPERIMENTAL
Intervention: Sublingual administration of carboprost combined with oxytocin (20IU oxytocin and small pot drip of 10IU oxytocin after delivery)
Number of subjects: 180

Group type: COMPARATOR
Intervention: 1mg of carboprost when the fetal head came out and then intramuscular injection of 20IU oxytocin
Number of subjects: 180
Study: 33983840

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum during mechanical ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (colostrum only for gastrointestinal nutrition)
Number of subjects: 0
Study: 32430987

Group type: EXPERIMENTAL
Intervention: Negative pressure drainage assisted irrigation (NPDI)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 58
Study: 33429093

Group type: EXPERIMENTAL
Intervention: Thermal Water (TW) group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Dryland (DL) group
Number of subjects: 34
Study: 32668036

Group type: EXPERIMENTAL
Intervention: Endodontic treatment with post-installation at the first visit (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Endodontic treatment with post-installation at the second visit (group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 100
Study: 35821134

Group type: EXPERIMENTAL
Intervention: 3-step etch-and-rinse (3-ER)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 2-step etch-and-rinse (2-ER)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 2-step self-etch (2-SE)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 1-step self-etch (1-SE)
Number of subjects: 39
Study: 36495881

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 32854568

Group type: EXPERIMENTAL
Intervention: Roflumilast 250 µg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 32544854

Group type: EXPERIMENTAL
Intervention: Adaptive memory span training (20 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-adaptive easy version of memory span task (20 sessions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subjects carrying the non-risk allele (C) of rs1344706
Number of subjects: 60
Study: 35960160

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34234540

Group type: EXPERIMENTAL
Intervention: Proprioceptive training (ProT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Craniocervical flexor training (CCFT)
Number of subjects: 42
Study: 35977951

Group type: COMPARATOR
Intervention: placebo (relaxing music)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: tinnitus retraining therapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: auditory discrimination therapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: enriched acoustic environment
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: binaural beats therapy
Number of subjects: 89
Study: 33684925

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with chemotherapy
Number of subjects: 68
Study: 34347918

Group type: EXPERIMENTAL
Intervention: SVV maintained at 7-10%
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SVV maintained at 3-6%
Number of subjects: 54
Study: 33010438

Group type: EXPERIMENTAL
Intervention: 135° humeral inclination
Number of subjects: 14

Group type: COMPARATOR
Intervention: 155° humeral inclination
Number of subjects: 14